These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 16892352)

  • 1. Substituted isoxazoles as potent inhibitors of p38 MAP kinase.
    Laufer SA; Margutti S; Fritz MD
    ChemMedChem; 2006 Feb; 1(2):197-207. PubMed ID: 16892352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region.
    Laufer SA; Hauser DR; Domeyer DM; Kinkel K; Liedtke AJ
    J Med Chem; 2008 Jul; 51(14):4122-49. PubMed ID: 18578517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological evaluation of trisubstituted imidazole derivatives as inhibitors of p38alpha mitogen-activated protein kinase.
    Kim DK; Lim JH; Lee JA; Dewang PM
    Bioorg Med Chem Lett; 2008 Jul; 18(14):4006-10. PubMed ID: 18571921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the ribose and phosphate binding site of p38 mitogen-activated protein (MAP) kinase: synthesis and biological testing of 2-alkylsulfanyl-, 4(5)-aryl-, 5(4)-heteroaryl-substituted imidazoles.
    Pierre Koch ; Christiane Bäuerlein ; Hartmut Jank ; Stefan Laufer
    J Med Chem; 2008 Sep; 51(18):5630-40. PubMed ID: 18763757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isoxazolone based inhibitors of p38 MAP kinases.
    Laufer SA; Margutti S
    J Med Chem; 2008 Apr; 51(8):2580-4. PubMed ID: 18373337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aza-analogue dibenzepinone scaffolds as p38 mitogen-activated protein kinase inhibitors: design, synthesis, and biological data of inhibitors with improved physicochemical properties.
    Karcher SC; Laufer SA
    J Med Chem; 2009 Mar; 52(6):1778-82. PubMed ID: 19253982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tri- and tetrasubstituted imidazoles as p38α mitogen-activated protein kinase inhibitors.
    Laufer S; Hauser D; Stegmiller T; Bracht C; Ruff K; Schattel V; Albrecht W; Koch P
    Bioorg Med Chem Lett; 2010 Nov; 20(22):6671-5. PubMed ID: 20934337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and biological evaluation of novel disubstituted dibenzosuberones as highly potent and selective inhibitors of p38 mitogen activated protein kinase.
    Koeberle SC; Fischer S; Schollmeyer D; Schattel V; Grütter C; Rauh D; Laufer SA
    J Med Chem; 2012 Jun; 55(12):5868-77. PubMed ID: 22676210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CoMFA and docking studies on triazolopyridine oxazole derivatives as p38 MAP kinase inhibitors.
    Shashi Nayana MR; Sekhar YN; Siva Kumari N; Mahmood SK; Ravikumar M
    Eur J Med Chem; 2008 Jun; 43(6):1261-9. PubMed ID: 17825954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyridinylquinoxalines and pyridinylpyridopyrazines as lead compounds for novel p38 alpha mitogen-activated protein kinase inhibitors.
    Koch P; Jahns H; Schattel V; Goettert M; Laufer S
    J Med Chem; 2010 Feb; 53(3):1128-37. PubMed ID: 20078117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and biological evaluation of phenylamino-substituted 6,11-dihydro-dibenzo[b,e]oxepin-11-ones and dibenzo[a,d]cycloheptan-5-ones: novel p38 MAP kinase inhibitors.
    Laufer SA; Ahrens GM; Karcher SC; Hering JS; Niess R
    J Med Chem; 2006 Dec; 49(26):7912-5. PubMed ID: 17181176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacophore modeling of diverse classes of p38 MAP kinase inhibitors.
    Sarma R; Sinha S; Ravikumar M; Kishore Kumar M; Mahmood SK
    Eur J Med Chem; 2008 Dec; 43(12):2870-6. PubMed ID: 18406015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors.
    Das J; Moquin RV; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2652-7. PubMed ID: 18359226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A p38 mitogen-activated protein kinase inhibitor screening method using growth recovery of Escherichia coli as an index.
    Kawai K; Saito A; Sudo T; Osada H
    Anal Biochem; 2009 May; 388(1):128-33. PubMed ID: 19248755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigations of SCIO-469-like compounds for the inhibition of p38 MAP kinase.
    Laufer S; Lehmann F
    Bioorg Med Chem Lett; 2009 Mar; 19(5):1461-4. PubMed ID: 19195885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and SAR of phenylamino-substituted 5,11-dihydro-dibenzo[a,d]cyclohepten-10-ones and 11H-dibenzo[b,f]oxepin-10-ones as p38 MAP kinase inhibitors.
    Dorn A; Schattel V; Laufer S
    Bioorg Med Chem Lett; 2010 May; 20(10):3074-7. PubMed ID: 20418099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amide-based inhibitors of p38alpha MAP kinase. Part 1: discovery of novel N-pyridyl amide lead molecules.
    Luedtke GR; Schinzel K; Tan X; Tester RW; Nashashibi I; Xu YJ; Dugar S; Levy DE; Jung J
    Bioorg Med Chem Lett; 2010 Apr; 20(8):2556-9. PubMed ID: 20346653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification, synthesis, and biological evaluation of 6-[(6R)-2-(4-fluorophenyl)-6-(hydroxymethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3(2H)-one (AS1940477), a potent p38 MAP kinase inhibitor.
    Asano T; Yamazaki H; Kasahara C; Kubota H; Kontani T; Harayama Y; Ohno K; Mizuhara H; Yokomoto M; Misumi K; Kinoshita T; Ohta M; Takeuchi M
    J Med Chem; 2012 Sep; 55(17):7772-85. PubMed ID: 22905713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biphenyl amide p38 kinase inhibitors 1: Discovery and binding mode.
    Angell RM; Bamborough P; Cleasby A; Cockerill SG; Jones KL; Mooney CJ; Somers DO; Walker AL
    Bioorg Med Chem Lett; 2008 Jan; 18(1):318-23. PubMed ID: 18006306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of ML3403 ({4-[5-(4-fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-(1-phenylethyl)-amine), a 4-Pyridinylimidazole-type p38 mitogen-activated protein kinase inhibitor.
    Kammerer B; Scheible H; Albrecht W; Gleiter CH; Laufer S
    Drug Metab Dispos; 2007 Jun; 35(6):875-83. PubMed ID: 17344341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.